Baghel Kavita, Kazmi Hasan Raza, Chandra Abhijit, Raj Saloni, Srivastava Rajeshwar Nath
Department of Surgical Gastroenterology, King George's Medical University, Lucknow, India.
Department of Biomedical Sciences, PennVet, University of Pennsylvania, Philadelphia, PA, USA.
Asia Pac J Clin Oncol. 2019 Oct;15(5):e120-e125. doi: 10.1111/ajco.13129. Epub 2019 Feb 10.
We investigated prognostic significance of methylation status of MASPIN gene and its protein expression in normal subjects, cholelithiasis and gallbladder cancer (GBC) patients.
MASPIN protein expression and its promoter methylation in gallbladder tissue of cholelithiasis (n = 36), GBC (n = 46) and controls (n = 25) were investigated. Clinicopathological parameters and prognosis of patients with GBC were correlated with protein expression of MASPIN. Survival analysis of GBC patients was performed using Kaplan-Meier method.
Significant increased (P < 0.0001) protein expression of MASPIN was observed in GBC as compared to cholelithiasis, whereas negligible expression was found in normal tissues. Methylation-specific PCR revealed statistical significant (P = 0.005) difference in methylation status of MASPIN promoter between gallstone and GBC patients. Significant association was observed between methylation profile with protein expression of MASPIN (P = 0.004), stage (P = 0.011) and cellular differentiation (P = 0.012) for GBC. Also, significant (P = 0.004) difference in survival was observed for malignant patients having demethylated MASPIN promoter. Further significant negative correlation (Pearson's coefficient [r] = -0.617; P < 0.0001) was observed between MASPIN expression and survival of cancer patients after surgery. Overall survival was significantly shorter (P ≤ 0.0001; hazard ratio [HR] for death = 2.84; 95% confidence interval [CI], 0.09865-0.3683) in patients of GBC with MASPIN expression ≥169.56 pg/mg (median survival; 10 months) with compared to those with expression <169.56 pg/mg (median survival; 16 months).
Overexpression of MASPIN protein may play an important role in malignant progression and is correlated with a poor prognosis. Also MASPIN DNA methylation can be used as a novel therapeutic target for treating GBC.
我们研究了正常受试者、胆石症患者和胆囊癌(GBC)患者中MASPIN基因甲基化状态及其蛋白表达的预后意义。
研究了胆石症患者(n = 36)、GBC患者(n = 46)和对照组(n = 25)胆囊组织中MASPIN蛋白表达及其启动子甲基化情况。GBC患者的临床病理参数和预后与MASPIN蛋白表达相关。采用Kaplan-Meier法对GBC患者进行生存分析。
与胆石症相比,GBC中MASPIN蛋白表达显著增加(P < 0.0001),而在正常组织中表达可忽略不计。甲基化特异性PCR显示,胆石症患者和GBC患者之间MASPIN启动子甲基化状态存在统计学显著差异(P = 0.005)。观察到GBC的甲基化谱与MASPIN蛋白表达(P = 0.004)、分期(P = 0.011)和细胞分化(P = 0.012)之间存在显著关联。此外,MASPIN启动子去甲基化的恶性患者生存情况存在显著差异(P = 0.004)。术后癌症患者的MASPIN表达与生存之间还存在显著的负相关(Pearson系数[r] = -0.617;P < 0.0001)。MASPIN表达≥169.56 pg/mg(中位生存期;10个月)的GBC患者的总生存期明显短于表达<169.56 pg/mg(中位生存期;16个月)的患者(P≤0.0001;死亡风险比[HR] = 2.84;95%置信区间[CI],0.09865 - 0.3683)。
MASPIN蛋白的过表达可能在恶性进展中起重要作用,并与预后不良相关。此外,MASPIN DNA甲基化可作为治疗GBC的新治疗靶点。